Nichols William Garrett

SEC source: 0001193125-26-027409 · ownership.xml · derivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,500

Underlying: Common Stock · 136,500 shares

Expires 2036-01-26

F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 26, 2026, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-100320 · ownership.xml · derivative · entry 3

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,377

Underlying: Common Stock · 937 shares

Expires 2033-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

F2 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-100320 · ownership.xml · nonDerivative · entry 2

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,493

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

SEC source: 0000950170-25-100320 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,430

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

SEC source: 0000950170-25-093035 · ownership.xml · derivative · entry 3

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,314

Underlying: Common Stock · 781 shares

Expires 2033-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

F2 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-093035 · ownership.xml · nonDerivative · entry 2

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,493

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

SEC source: 0000950170-25-093035 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,274

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

SEC source: 0000950170-25-042728 · ownership.xml · derivative · entry 5

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,095

Underlying: Common Stock · 13,905 shares

Expires 2033-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

F4 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-042728 · ownership.xml · derivative · entry 4

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,416

Underlying: Common Stock · 4,584 shares

Expires 2032-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

F3 · derivative.exercise_date: The first 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on September 12, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The remaining 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on the first anniversary of the date in which the Reporting Person converts to a full-time employee, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0000950170-25-042728 · ownership.xml · nonDerivative · entry 3

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,493

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.36 to $9.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.

SEC source: 0000950170-25-042728 · ownership.xml · nonDerivative · entry 2

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

SEC source: 0000950170-25-042728 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on 11/22/2024.

SEC source: 0000950170-25-021284 · ownership.xml · derivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,250

Underlying: Common Stock · 107,250 shares

Expires 2035-02-12

F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following February 12, 2025, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000950170-25-006723 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,320

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.

SEC source: 0000950170-25-004195 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,748

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.

SEC source: 0000950170-24-132928 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,547

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.

SEC source: 0000950170-24-084759 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,482

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.

SEC source: 0000950170-24-083397 · ownership.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,357

F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.

SEC source: 0001209191-23-056986 · doc4.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,126

F1 · shares: These shares were withheld by the Issuer to satisfy tax withholding obligations associated with the vesting and settlement of restricted stock units.

SEC source: 0001209191-23-056804 · doc4.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,301

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on June 30, 2024, and the remaining 50% on December 31, 2024, in each case subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001209191-23-026569 · doc4.xml · derivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2033-04-28

F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following April 28, 2023, subject to the Reporting Person's continued service on each vesting date.

SEC source: 0000899243-22-037228 · doc4.xml · nonDerivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,479

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on November 28, 2023, and the remaining 50% on November 28, 2024, in each case subject to the Reporting Person's continued service on such vesting date.

SEC source: 0000899243-22-031059 · doc4.xml · derivative · entry 1

Nichols William Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-09-12

F1 · derivative.exercise_date: The first 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on September 12, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The remaining 100,000 shares underlying this option shall vest as follows: 25% shall vest and become exercisable on the first anniversary of the date in which the Reporting Person converts to a full-time employee, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001209191-20-008297 · doc4.xml · nonDerivative · entry 2

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,066

F1 · kind: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to restricted stock unit awards granted on January 24, 2017 and January 23, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.705, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001209191-20-008297 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,871

F1 · kind: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to restricted stock unit awards granted on January 24, 2017 and January 23, 2019.

SEC source: 0001209191-20-004688 · doc4.xml · derivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,500

Underlying: Common Stock · 192,500 shares

Expires 2030-01-20

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-20-002630 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,421

F1 · kind: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.185, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Includes 2,045 shares of the Issuer's common stock acquired by the reporting person on September 10, 2019 pursuant to an employee stock purchase program.

SEC source: 0001209191-19-043295 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,056

F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.49 to $3.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-19-031951 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,681

F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.44 to $3.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-19-008277 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,376

F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the RSUs will vest in full on December 31, 2019.

SEC source: 0001209191-19-005995 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,376

F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20 to $2.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-19-005359 · doc4.xml · derivative · entry 2

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-01-22

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-19-005359 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,471

F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 25,000 shares subject to the RSUs will vest on the six-month anniversary of the date of grant, 25,000 shares subject to the RSUs will vest on the one-year anniversary of the date of grant, 25,000 shares subject to the RSUs will vest on the 18-month anniversary of the date of grant, and 50,000 shares subject to the RSUs will vest on the two-year anniversary of the date of grant.

SEC source: 0001209191-18-030138 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,471

F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $4.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-18-007698 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,151

F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.661 to $4.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001209191-18-005821 · doc4.xml · derivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,500

Underlying: Common Stock · 148,500 shares

Expires 2028-01-24

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-17-032836 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,481

F1 · shares: The shares were sold in payment of the reporting person's tax liability incurred upon the vesting of shares subject to a restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.775, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4

SEC source: 0001209191-17-023888 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,193

F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001209191-17-005779 · doc4.xml · derivative · entry 2

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,750

Underlying: Common Stock · 60,750 shares

Expires 2027-01-23

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-17-005779 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,606

F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs shall vest on January 24, 2018, 25% of the RSUs shall vest on January 24, 2019, 25% of the RSUs shall vest on January 24, 2020 and the remaining 25% of the RSUs shall vest on January 24, 2021.

SEC source: 0001209191-16-142036 · doc4.xml · nonDerivative · entry 1

Nichols Garrett · CIK 0001618364 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,231

F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).